In this observational cohort, topiramate monotherapy was associated with reductions in pain severity and headache-related disability and was generally well tolerated. These findings suggest that topiramate may be considered as a potential first-line or alternative prophylactic option in selected patients, particularly when treatment choices are limited or polypharmacy is undesirable.
Shafiyev et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: